Generic Ozempic tentatively OK
The FDA has given tentative approval to an abbreviated new drug application for a generic semaglutide injection — a formal regulatory step that clears the application but does not yet allow the drug to be sold. (hcplive.com). The paperwork move is recorded publicly by the agency and is the key milestone before final approval and market entry can be authorized. (hcplive.com)
The Food and Drug Administration has tentatively cleared the first U.S. generic version of semaglutide injection, the active ingredient in Ozempic, but pharmacies still cannot sell it. (apotex.com) Apotex said on April 10, 2026 that the tentative approval covers its abbreviated new drug application for semaglutide injection, filed with partner Orbicular Pharmaceutical Technologies. HCPLive reported the application is the first tentative approval for a generic semaglutide injection in the United States. (apotex.com) (hcplive.com) A tentative approval means the Food and Drug Administration found the application meets the scientific standards for approval, but patent or exclusivity barriers still block a commercial launch. The agency records those decisions in its Orange Book, the public database for approved drugs and therapeutic equivalents. (hcplive.com) (fda.gov) Semaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, a class of drugs that helps lower blood sugar and can reduce appetite. Novo Nordisk’s Ozempic injection won its first Food and Drug Administration approval on December 5, 2017 for adults with type 2 diabetes. (accessdata.fda.gov) (drugs.com) The application matters because semaglutide has become one of the most sought-after drug ingredients in the United States, with demand stretching from diabetes treatment to off-label weight-loss use. Apotex said final approval would depend on when it becomes eligible under the remaining patent and exclusivity rules. (hcplive.com) (prnewswire.com) Patent fights are central to the timeline. The American Bar Association wrote in 2024 that the Federal Trade Commission had disputed Orange Book listings tied to Ozempic, while generic challengers and Novo Nordisk were already fighting over semaglutide patents in U.S. courts and administrative reviews. (americanbar.org) Independent patent analysts have projected that U.S. generic Ozempic entry is unlikely before 2032, though that date depends on litigation, settlements, and any changes to listed patents or exclusivities. Apotex did not announce a launch date in its April 10 statement. (markmanadvisors.com) (apotex.com) For now, the decision is a regulatory checkpoint, not a store-shelf change. The next step is final approval, and that can happen only after the legal and exclusivity barriers in front of semaglutide injection are cleared. (fda.gov) (hcplive.com)
